1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Vaccines, Oncology Frame Q4 Contrasts Between Pfizer And GSK

The Battle Of The RSV Vaccines Is Only Part Of The Story

 
• By Andy Smith

While attempting to move beyond post-pandemic unfavorable revenue comparisons, other unfavorable comparisons emerged at Pfizer.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Unlike Johnson & Johnson the previous week, Pfizer Inc.’s* stock price traded up by about 1% in the premarket on its fourth-quarter and full-year 2023 results announcement. This accelerated through its conference call with Pfizer’s stock price initially opening up by about 2% in normal trading. But like J&J, within a few minutes of the market open, Pfizer’s stock headed into the red and closed down by nearly 2% compared with the NYSE Arca Pharmaceutical Index’s (DRG’s) modest loss for the day.

I wondered why investors initially warmed to Pfizer’s announcement. Fourth-quarter revenues fell by 41% on the same quarter of 2022 as sales of Pfizer’s COVID-19 vaccine Comirnaty and antiviral Paxlovid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

More from Business

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.